Hyperlipidemia
Methodology & AI Transparency ⓘ
Hyperlipidemia Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Under Cholesterol, Triglycerides & Lipids diagnostic criteria (E78.5), workup for Hyperlipidemia integrates fasting lipid fractionation [Hyperlipidemia E78.5] with evidence-graded therapy tailored to Apolipoprotein B (ApoB) [Hyperlipidemia E78.5] response.
- 2 Real-world patient consensus: Federal ICD-10-CM code E78.5 categorizes Hyperlipidemia under Cholesterol, Triglycerides & Lipids.
- 3 Typical cash cost range: Workup highlights for Hyperlipidemia (E78.5): fasting lipid fractionation [Hyperlipidemia E78.5].
- 4 Top reported side effects / signs: Key Cholesterol & Lipids biomarkers for Hyperlipidemia (E78.5): Apolipoprotein B (ApoB) [Hyperlipidemia E78.5] & LDL Cholesterol [Hyperlipidemia E78.5] (< 85 mg/dL (E78.5)).
Ask our AI Specialists anything about Hyperlipidemia
What Is Hyperlipidemia?
Under Cholesterol, Triglycerides & Lipids diagnostic criteria (E78.5), workup for Hyperlipidemia integrates fasting lipid fractionation [Hyperlipidemia E78.5] with evidence-graded therapy tailored to Apolipoprotein B (ApoB) [Hyperlipidemia E78.5] response.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Hyperlipidemia (E78.5, Cholesterol & Lipids) reflects impaired hepatic LDL-receptor in Hyperlipidemia (E78.5: clearance). longitudinal control is benchmarked via Apolipoprotein B (ApoB) [Hyperlipidemia E78.5].
Common Symptoms & Clinical Signs
- • Presentation of Hyperlipidemia (E78.5): elevated triglyceride-to-HDL ratio [Hyperlipidemia E78.5]
- • Secondary Hyperlipidemia clinical sign: premature family history in Hyperlipidemia (E78.5: of coronary stenting,)
- • Symptom flares in Hyperlipidemia correlating with Apolipoprotein B (ApoB) [Hyperlipidemia E78.5] deviation outside < 70 mg/dL (< 55 mg/dL high risk) (E78.5)
- • Functional cholesterol & lipids impact requiring fasting lipid fractionation [Hyperlipidemia E78.5] evaluation (E78.5)
Hyperlipidemia Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E78.5 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cholesterol, Triglycerides & Lipids | NLM Clinical Tables |
| Diagnostic / Lab Marker: Apolipoprotein B (ApoB) [Hyperlipidemia E78.5] | < 70 mg/dL (< 55 mg/dL high risk) (E78.5) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: LDL Cholesterol [Hyperlipidemia E78.5] | < 85 mg/dL (E78.5) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Triglycerides [Hyperlipidemia E78.5] | < 100 mg/dL (E78.5) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Hyperlipidemia
Treatment selection for Hyperlipidemia depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Hyperlipidemia)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed high: What a 1,148-Participant Study Found The significant reductions of atherogenic lipids including LDL-C, non-HDL-C, and apolipoprotein B seen with evolocumab are similar in patients with and without mixed high cholesterol. Cardiovascular drugs and therapy • 2016-06-15 • Phase III Randomized Trial | N = 1,148 | 96/100 | PMID 27240673 ↗ |
| New Insights on Fixed-dose combination ezetimibe+atorvastatin lowers LDL-C equivalent to: What a 353-Participant Study Found Hypercholesterolemic patients administered ezetimibe/atorvastatin 10/20 and 10/40 mg FDC had equivalent LDL-C lowering. Fundamental & clinical pharmacology • 2015-04-15 • Randomized Controlled Trial | N = 353 | 93/100 | PMID 25431239 ↗ |
| New Insights on Benefits and safety of Single-Pill Combination of Rosuvastatin and Ezetimibe in: What a 305-Participant Study Found The results suggest that SPC R10/E10 improve LDL-C reduction and goal achievement in Chinese patients with primary high cholesterol not adequately controlled on statin therapy, without new safety findings. Advances in therapy • 2023-12-15 • Phase III Randomized Trial | N = 305 | 93/100 | PMID 37770770 ↗ |
| New Insights on Benefits and safety of ongericimab given by prefilled syringe or autoinjector in: What a 255-Participant Study Found In Chinese patients with primary high cholesterol and mixed high cholesterol, a 12-week treatment regimen with ongericimab administered by PFS or AI significantly reduced LDL-C and other lipid parameters, proving to be safe... Nutrition, metabolism, and cardiovascular diseases : NMCD • 2024-09-15 • Phase III Randomized Trial | N = 255 | 93/100 | PMID 38866609 ↗ |
| New Insights on Differences between rosuvastatin and atorvastatin in lipid-lowering action and: What a 1,049-Participant Study Found Rosuvastatin 5 mg and atorvastatin 10 mg have a similar lowering effect on non-HDL-C, but might be different in terms of adverse effect on glucose levels. Circulation journal : official journal of the Japanese Circulation Society • 2014-01-15 • Randomized Controlled Trial | N = 1,049 | 90/100 | PMID 25186922 ↗ |
Hyperlipidemia Patient Community & “People Like Me” Threads
Filter Hyperlipidemia community threads and patient logs by age, biological sex, dosage, and treatment duration.